RESEARCH MONOGRAPH · KDC-MN-300

FOXO4-DRI Peptide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

53/100

The cell-penetrating senolytic peptide thats got one striking paper and a thin replication record, exciting in vitro and hedge-worthy in vivo

FOXO4-DRI is the Peter de Keizer lab peptide from the 2017 Cell paper (Baar et al) that genuinely caused a stir in the senolytic field. The design is elegant: take a fragment of FOXO4 that includes the p53 interaction domain, build it with D-retro-inverso amino acids (so it's protease-resistant and the chirality flips), add a cell-penetrating sequence. The mechanism is that the peptide enters senescent cells, disrupts the FOXO4-p53 interaction that normally keeps p53 sequestered away from mitochondria in senescent cells, free p53 translocates to mitochondria, and you get apoptosis selective to senescent cells where this interaction is uniquely loaded.

The original paper showed striking phenotypic improvement in aged mice: hair regrowth, kidney function recovery, improved physical performance. The senolytic selectivity argument was that the FOXO4-p53 interaction is upregulated specifically in senescent cells, so you'd kill senescent cells while sparing the rest of the p53-having tissue.

What's happened since is the part that needs a hedge. The replication record is genuinely thin. There have been confirmatory in vitro studies of the basic FOXO4-p53 disruption mechanism, but the dramatic whole-animal phenotypic effects from the original paper have not been replicated at the scale you'd want for a compound this prominently positioned. The de Keizer lab has continued to publish but the broader senolytic field has tilted toward navitoclax derivatives, BCL-XL-targeting PROTACs, and the dasatinib-plus-quercetin combinations rather than FOXO4-DRI.

What we like: the mechanism story is elegant, the in vitro work is reproducible, and as a research tool for studying the FOXO4-p53 interaction specifically it's a clean reagent. The D-retro-inverso design solves the protease degradation problem that kills most peptide research tools in vivo.

What we dont love is the gap between the original headline results and the thinner replication record. We're genuinely not sure how to weight the in vivo data and that's a real caveat for anyone planning serious work with this compound.

Sourcing for FOXO4-DRI is okay. The peptide is challenging (D-retro-inverso synthesis is more demanding, the cell-penetrating sequence has to fold correctly) and supplier QC variance is wider than for standard L-peptides. HPLC plus mass spec is mandatory, the D-residues should be verified explicitly, and the bioactivity confirmation should be in-house if the experiment depends on the senolytic effect specifically.

Evidence: 35
Mechanism: 70
Reliability: 45
Safety: 65
Sourcing: 55
Value: 50
Signal: 55
Staying power: 45

Plain-language summary Intrigue 75 / 100

FOXO4-DRI is a designer cell-penetrating peptide developed by de Keizer's group in the Netherlands as a senolytic. It is a retroinverso D-amino-acid version (mirror-image, protease-resistant) of part of the FOXO4 sequence. In senescent cells, FOXO4 traps p53 in the nucleus and prevents it from triggering apoptosis. The DRI peptide competes for that interaction, releases p53, and allows it to drive selective apoptosis in senescent cells while sparing normal cells. The 2017 Cell paper showed striking restoration of fitness, kidney function, and fur density in old mice. Independent replication has been limited and the peptide has not advanced to human trials. Genuinely intriguing biology with single-laboratory dominance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Cell-penetrating peptide senolytic

A retroinverso D-amino acid peptide that disrupts the FOXO4-p53 interaction in senescent cells, selectively triggering apoptosis.

Abstract

FOXO4-DRI (FOXO4-D-retroinverso peptide; sequence ltlrkepaseiaqsileayqqgs in D-amino acids; molecular weight approximately 2700 Da) is a designed cell-penetrating peptide senolytic developed by de Keizer and colleagues at the Hubrecht Institute. The compound is a retroinverso peptide derived from the FOXO4 sequence that competitively disrupts the FOXO4-p53 interaction; in senescent cells, FOXO4 sequesters nuclear p53 and prevents apoptosis. The DRI peptide releases p53, which translocates to mitochondria and triggers selective apoptosis in senescent cells while sparing healthy cells (which do not depend on the FOXO4-p53 interaction for survival). Mouse studies (Cell 2017) demonstrated dramatic rejuvenation of fur density, kidney function, and physical performance in aged mice. The retroinverso D-amino acid construction confers protease resistance; cell penetration is supported by an attached penetratin sequence. No human clinical trials at this writing. The compound is a research tool for academic senolytic biology.

Mechanism of action

Retroinverso D-amino acid peptide that disrupts FOXO4-p53 interaction; releases p53 to trigger selective apoptosis in senescent cells.

Reported research dose ranges

Mouse studies 5 mg/kg intraperitoneal three times in the published literature.

References

Baar MP, et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 2017.
de Keizer PLJ. The fountain of youth by targeting senescent cells? Trends Mol Med 2017.
van der Horst A, Burgering BMT. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-300

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

FOXO4-DRI Peptide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs